US 3078305A
· Dobratz
· 1963
[cited by applicant]
US 5100883A
· Schiehser
· 1992
[cited by applicant]
US 5118677A
· Caufield
· 1992
[cited by applicant]
US 5118678A
· Kao
· 1992
[cited by applicant]
US 5120842A
· Failli
· 1992
[cited by applicant]
US 5151413A
· Caufield
· 1992
[cited by applicant]
US 5256790A
· Nelson
· 1993
[cited by applicant]
US 5258389A
· Goulet
· 1993
[cited by applicant]
US 5521184A
· Zimmermann
· 1996
[cited by applicant]
US 5650415A
· Tang
· 1997
[cited by applicant]
US 5656643A
· Spada
· 1997
[cited by applicant]
US 5712291A
· D'Amato
· 1998
[cited by applicant]
US 5728813A
· Lyman
· 1998
[cited by applicant]
US 5747498A
· Schnur
· 1998
[cited by applicant]
US 5770599A
· Gibson
· 1998
[cited by applicant]
US 5789427A
· Chen
· 1998
[cited by applicant]
US 5792783A
· Tang
· 1998
[cited by applicant]
US 5892112A
· Levy
· 1999
[cited by applicant]
US 5969110A
· Beckmann
· 1999
[cited by applicant]
US 5981245A
· Fox
· 1999
[cited by applicant]
US 5990141A
· Hirth
· 1999
[cited by applicant]
US 6057124A
· Bartley
· 2000
[cited by applicant]
US 6111090A
· Gorman
· 2000
[cited by applicant]
US 6232447B1
· Cerretti
· 2001
[cited by applicant]
US 6235764B1
· Larson
· 2001
[cited by applicant]
US 6258812B1
· Bold
· 2001
[cited by applicant]
US 6413932B1
· Cerretti
· 2002
[cited by applicant]
US 6515004B1
· Misra
· 2003
[cited by applicant]
US 6596852B2
· Cerretti
· 2003
[cited by applicant]
US 6630500B2
· Gingrich
· 2003
[cited by applicant]
US 6656963B2
· Firestone
· 2003
[cited by applicant]
US 6713485B2
· Carter
· 2004
[cited by applicant]
US 6727225B2
· Wiley
· 2004
[cited by applicant]
US 7025962B1
· Gorman
· 2006
[cited by applicant]
US 7618632B2
· Collins
· 2009
[cited by applicant]
US 7812135B2
· Smith
· 2010
[cited by applicant]
US 8388967B2
· Smith
· 2013
[cited by applicant]
US 8586023B2
· Shiku
· 2013
[cited by applicant]
US 8591886B2
· Ponath
· 2013
[cited by applicant]
US 20030105091A1
· Riedl
· 2003
[cited by applicant]
US 20090012085A1
· Baum
· 2009
[cited by applicant]
US 20200055845A1
· Lanman
· 2020
[cited by applicant]
US 20220168280A1
· Lanman
· 2022
[cited by applicant]
CN 108779097A
· 2018
[cited by applicant]
CN 106687457B
· 2020
[cited by applicant]
DE 19629652A1
· 1998
[cited by applicant]
EA 202191381A1
· 2021
[cited by applicant]
EP 0090505A
· 1983
[cited by applicant]
EP 407122A
· 1991
[cited by applicant]
EP 520722A
· 1992
[cited by applicant]
EP 566226A
· 1993
[cited by applicant]
EP 606046A
· 1994
[cited by applicant]
EP 0682027A
· 1995
[cited by applicant]
EP 0787772A2
· 1997
[cited by applicant]
EP 0818442A2
· 1998
[cited by applicant]
EP 0837063A
· 1998
[cited by applicant]
EP 931788A
· 1999
[cited by applicant]
EP 970070A
· 2000
[cited by applicant]
EP 0780386B1
· 2002
[cited by applicant]
EP 1181017B1
· 2003
[cited by applicant]
EP 1004578B1
· 2004
[cited by applicant]
EP 1786785B9
· 2013
[cited by applicant]
EP 1947183B1
· 2013
[cited by applicant]
EP 1866339B2
· 2021
[cited by applicant]
JP H02233610A
· 1990
[cited by applicant]
JP 2002047292A
· 2002
[cited by applicant]
JP 2011524903A
· 2011
[cited by applicant]
JP 2019031476A
· 2019
[cited by applicant]
TW 200633693A
· 2006
[cited by applicant]
WO 1990005719A1
· 1990
[cited by applicant]
WO 1992005179A1
· 1992
[cited by applicant]
WO 1992020642A1
· 1992
[cited by applicant]
WO 1993011130A1
· 1993
[cited by applicant]
WO 1994002136A1
· 1994
[cited by applicant]
WO 1994002485A1
· 1994
[cited by applicant]
WO 1994009010A1
· 1994
[cited by applicant]
WO 1995009847A1
· 1995
[cited by applicant]
WO 1995014023A1
· 1995
[cited by applicant]
WO 1995016691A1
· 1995
[cited by applicant]
WO 1995019774A1
· 1995
[cited by applicant]
WO 1995019970A1
· 1995
[cited by applicant]
WO 1996027583A1
· 1996
[cited by applicant]
WO 1996030347A1
· 1996
[cited by applicant]
WO 1996031510A1
· 1996
[cited by applicant]
WO 1996033172A1
· 1996
[cited by applicant]
WO 1996033980A1
· 1996
[cited by applicant]
WO 1996041807A1
· 1996
[cited by applicant]
WO 1997002266A1
· 1997
[cited by applicant]
WO 1997013771A1
· 1997
[cited by applicant]
WO 1997019065A1
· 1997
[cited by applicant]
WO 1997027199A1
· 1997
[cited by applicant]
WO 1997030034A1
· 1997
[cited by applicant]
WO 1997030044A1
· 1997
[cited by applicant]
WO 1997032880A1
· 1997
[cited by applicant]
WO 1997032881A1
· 1997
[cited by applicant]
WO 1997034895A1
· 1997
[cited by applicant]
WO 1997038983A1
· 1997
[cited by applicant]
WO 1997038994A1
· 1997
[cited by applicant]
WO 1997049688A1
· 1997
[cited by applicant]
WO 1998002434A1
· 1998
[cited by applicant]
WO 1998002437A1
· 1998
[cited by applicant]
WO 1998002438A1
· 1998
[cited by applicant]
WO 1998003516A1
· 1998
[cited by applicant]
WO 1998007697A1
· 1998
[cited by applicant]
WO 1998007726A1
· 1998
[cited by applicant]
WO 1998014449A1
· 1998
[cited by applicant]
WO 1998014450A1
· 1998
[cited by applicant]
WO 1998014451A1
· 1998
[cited by applicant]
WO 1998017662A1
· 1998
[cited by applicant]
WO 1998030566A1
· 1998
[cited by applicant]
WO 1998033768A1
· 1998
[cited by applicant]
WO 1998033798A2
· 1998
[cited by applicant]
WO 1998034915A1
· 1998
[cited by applicant]
WO 1998034918A1
· 1998
[cited by applicant]
WO 1999007675A1
· 1999
[cited by applicant]
WO 1999007701A1
· 1999
[cited by applicant]
WO 1999020758A1
· 1999
[cited by applicant]
WO 1999029667A1
· 1999
[cited by applicant]
WO 1999035132A1
· 1999
[cited by applicant]
WO 1999035146A1
· 1999
[cited by applicant]
WO 1999040196A1
· 1999
[cited by applicant]
WO 1999045009A1
· 1999
[cited by applicant]
WO 1999052889A1
· 1999
[cited by applicant]
WO 1999052910A1
· 1999
[cited by applicant]
WO 1999061422A1
· 1999
[cited by applicant]
WO 2000002871A1
· 2000
[cited by applicant]
WO 2000012089A1
· 2000
[cited by applicant]
WO 2000059509A1
· 2000
[cited by applicant]
WO 2001003720A2
· 2001
[cited by applicant]
WO 2001032651A1
· 2001
[cited by applicant]
WO 2001037820A2
· 2001
[cited by applicant]
WO 2002055501A2
· 2002
[cited by applicant]
WO 2002059110A1
· 2002
[cited by applicant]
WO 2002066470A1
· 2002
[cited by applicant]
WO 2002068406A2
· 2002
[cited by applicant]
WO 2004005279A2
· 2004
[cited by applicant]
WO 2004007458A1
· 2004
[cited by applicant]
WO 2004007481A2
· 2004
[cited by applicant]
WO 2004009784A2
· 2004
[cited by applicant]
WO 2005005434A1
· 2005
[cited by applicant]
WO 2005007190A1
· 2005
[cited by applicant]
WO 2005011700A1
· 2005
[cited by applicant]
WO 2005016252A2
· 2005
[cited by applicant]
WO 2005055808A2
· 2005
[cited by applicant]
WO 2005115451A2
· 2005
[cited by applicant]
WO 2006061712A2
· 2006
[cited by applicant]
WO 2006083289A2
· 2006
[cited by applicant]
WO 2006121168A1
· 2006
[cited by applicant]
WO 2006122806A2
· 2006
[cited by applicant]
WO 2007133822A1
· 2007
[cited by applicant]
WO 2008070740A1
· 2008
[cited by applicant]
WO 2009036082A2
· 2009
[cited by applicant]
WO 2009055730A1
· 2009
[cited by applicant]
WO 2009154737A1
· 2009
[cited by applicant]
WO 2010003118A1
· 2010
[cited by applicant]
WO 2011028683A1
· 2011
[cited by applicant]
WO 2011051726A2
· 2011
[cited by applicant]
WO 2011090754A1
· 2011
[cited by applicant]
WO 2013039954A1
· 2013
[cited by applicant]
WO 2015175632A1
· 2015
[cited by applicant]
WO 2017087528A1
· 2017
[cited by applicant]
WO 2018119183A2
· 2018
[cited by applicant]
WO 2018217651A1
· 2018
[cited by applicant]
WO 2019051291A1
· 2019
[cited by applicant]
WO 2019213516A1
· 2019
[cited by applicant]
WO 2019213526A1
· 2019
[cited by applicant]
WO 2019217691A1
· 2019
[cited by applicant]
WO 2019232419A1
· 2019
[cited by applicant]
WO 2019241157A1
· 2019
[cited by applicant]
WO 2020050890A2
· 2020
[cited by applicant]
WO 2020061375A1
· 2020
[cited by applicant]
WO 2020102730A1
· 2020
[cited by applicant]
WO 2021097207A1
· 2021
[cited by applicant]
WO 2021097212A1
· 2021
[cited by applicant]
WO 2022076623A1
· 2022
[cited by applicant]
WO 2022109242A1
· 2022
[cited by applicant]
WO 2023172858A1
· 2023
[cited by applicant]
U.S. Appl. No. 18/988,163, filed Dec. 19, 2024, Parsons Andrew.
[cited by examiner]
Barnett et al., “Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors,” Biochem. J., vol. 385 (Pt. 2), pp. 399-408 (2005).
[cited by applicant]
Dasmahapatra et al. “In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines,” Clin. Cancer Res., vol. 10(15), pp. 52…
[cited by applicant]
European Patent Office, International Search Report in International Patent Application No. PCT/US2020/060421, dated Feb. 18, 2021.
[cited by applicant]
European Patent Office, Written Opinion in International Patent Application No. PCT/US2020/060421, dated Feb. 18, 2021.
[cited by applicant]
GenBank Accession No. NP_203524, “GTPas KRas isoform a [
[cited by applicant]
Gills et al., “The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt,” Expert. Opin. Investig. Drugs, vol. 13, pp. 787-797 (2004).
[cited by applicant]
Goldberg et al., “Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells,” Blood, vol. 110(1), pp. 186-192 (2007).
[cited by applicant]
Goldstein et al., “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model,” Clin Cancer Res, vol. 1(11), pp. 1311-1318 (1995).
[cited by applicant]
Huang et al., “Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck,” Cancer Res., vol. 59(8), pp. 1935-1940 (1999…
[cited by applicant]
Islam, et al., “1H and 11B NMR Study of p-Toluene Boronic Acid and Anhydride”, Analytical Sciences, vol. 18, pp. 363-366 (2002).
[cited by applicant]
Jin et al., “Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells,” Br. J. Cancer, vol. 91, pp. 1808-1812 (2004).
[cited by applicant]
Modjtahedi et al., “Immunotherapy of human tumor xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction,” Br. J. Cancer, vol. 67(2), pp. 254-261 (1993).
[cited by applicant]
Murray et al., “Kinetic and Mechanistic Investigations to Enable a Key Suzuki Coupling for Sotorasib Manufacture—What a Difference a Base Makes,” Organic Process Research & Development, pp. A-H, https://doi.org/10.1021/…
[cited by applicant]
Paez et al., “EGFR Mutations In Lung Cancer Correlation With Clinical Response to Gefitinib Therapy,” Science, vol. 304(5676), pp. 1497-1500 (2004).
[cited by applicant]
Pawar et al., “Process development and manufacture of potassium 2-fluoro-6-hydroxyphenyltrifluoroborate,” Tetrahedron, vol. 75, pp. 4266-4270 (2019).
[cited by applicant]
Perkins et al.“Synthesis of Programmable Tetra-ortho-Substituted Biaryl Compounds Using Diels-Alder Cycloadditions/Cycloreversions of Disubstituted Alkynyl Stannanes,” Journal of the American Chemical Society, vol. 130(…
[cited by applicant]
Remington's Pharmaceutical Sciences, 1435-1712 (18th ed., Mack Publishing Co, Easton, Pennsylvania, 1990 (Table of Contents Only).
[cited by applicant]
Sarkar et al., “Indole-3-carbinol and prostate cancer,” J Nutr., vol. 134(12 Suppl), pp. 3493S-3498S (2004).
[cited by applicant]
Teramoto et al., “Inhibitory Effect of Anti-Epidermal Growth Factor Receptor Antibody on a Human Gastric Cancer,” Cancer, vol. 77(8), pp. 1639-1645 (1996).
[cited by applicant]
Thompson et al., “PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma,” Clin. Cancer Res., vol. 13(6), pp. 1757-1761 (2007).
[cited by applicant]
Traxler, “Tyrosine kinase inhibitors in cancer treatment (Part II),” Exp. Opin. Ther. Patents, vol. 8(12), pp. 1599-1625 (1998).
[cited by applicant]
Yan et al., “Pharmacogenics and pharmacogenomics in oncology therapeutic antibody development,” BioTechniques, vol. 39, pp. 565-568 (2005).
[cited by applicant]
Yang et al., “Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt”, Cancer Res., vol. 64 (13), pp. 4394-4399 (2004…
[cited by applicant]
Yang et al., “Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy,” Cancer Res., vol. 59, pp. 1236-1243 (1999).
[cited by applicant]
Zhang et al., “Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor,” Organic Process Research and Development, vol. 26, pp. 3115-3125 (2022).
[cited by applicant]
Non Final Rejection issued in U.S. Appl. No. 18/988,163, dated Mar. 21, 2025.
[cited by applicant]